As part of its proprietary hepatitis C (HCV) inhibitor program, Achillion discovered and optimized the investigational compound, ACH-2684. ACH-2684 is a highly potent, pan-genotypic, second-generation protease inhibitor to which Achillion retains worldwide commercial rights. The compound has been advanced as a development candidate for the treatment of chronic HCV. ACH-2684 has completed Phase 1 development and ready for advancement into Phase 2.
• ACH-2684 retains potency against all HCV genotypes (GT) and exhibits equipotent activity against HCV GT 1a and 1b at an IC50 of approximately 100 picomolar
• ACH-2684 is metabolically stable and is rapidly and extensively partitioned in the liver, supporting once-daily dosing without the need for boosting in clinical development
• ACH-2684 was shown to be safe and well-tolerated in both healthy volunteers and HCV-infected patients during Phase 1 studies
• In Phase 1b studies, once-daily doses of ACH-2684 for 3 days displayed robust antiviral activity in cirrhotic and non-cirrhotic subjects with respective 3.67 log10 and 3.73 log10 mean maximal reductions in HCV RNA
• ACH-2684 has demonstrated a high barrier to resistance in vitro, retaining potent activity against commonly observed, highly-resistant, protease inhibitor-induced mutations at positions 155, 156, and 168
• In vitro testing has shown ACH-2684 is synergistic when combined with other inhibitors of HCV including NS5A inhibitors and NS5B nucleoside polymerase inhibitors
For more information about the highly potent, second-generation protease inhibitor, ACH-2684,please visit the Data Overview section.
ACH-2684 is an investigational compound. Its safety and efficacy have not been established.